You are viewing the site in preview mode
Skip to main content
Subgroups
Persons at risk
No. of events
Hazard ratio (95% CI) per 1-SD increment in log-transformed (log10 ) urinary NT-proBNPa
P for heterogeneity
Overall
3055
169
1.20 (1.07–1.35)
Age
40–64 years
1691
32
1.21 (0.75–1.96)
0.44
≥ 65 years
1364
137
1.25 (1.11–1.41)
Sex
Men
1286
92
1.21 (1.03–1.41)
0.48
Women
1769
77
1.30 (1.08–1.57)
Hypertension
No
1612
47
1.39 (1.06–1.81)
0.11
Yes
1443
122
1.17 (1.02–1.33)
Use of antihypertensive agents
No
2161
89
1.30 (1.09–1.56)
0.08
Yes
894
80
1.16 (0.98–1.37)
Diabetes
No
2597
122
1.26 (1.11–1.43)
0.24
Yes
458
47
0.96 (0.71–1.29)
Hypercholesterolemia
No
1610
79
1.20 (1.03–1.40)
0.54
Yes
1445
90
1.13 (0.95–1.35)
Use of lipid-lowering drugs
No
2630
130
1.19 (1.03–1.37)
0.65
Yes
425
39
1.34 (1.07–1.67)
Body mass index (kg/m 2 )
< 25
2268
117
1.25 (1.09–1.42)
0.38
≥ 25
787
52
1.18 (0.93–1.51)
eGFR level (mL/min/1.73 m 2 )
≥ 60
2742
130
1.30 (1.10–1.53)
0.07
< 60
313
39
1.18 (1.00–1.39)
The SD of log-transformed urinary NT-proBNP levels (pg/mL) was 0.215
Abbreviations : SD Standard deviation, NT-proBNP N-terminal pro–B-type natriuretic peptide, CI Confidence interval, eGFR Estimated glomerular filtration ratea Adjusted for age, sex, systolic blood pressure, antihypertensive agents, diabetes mellitus, serum total and high-density lipoprotein cholesterol levels, lipid-lowering agents, body mass index, electrocardiogram abnormality, estimated glomerular filtration rate, smoking habits, alcohol intake, and regular exercise. The variable relevant to the subgroup was excluded from each model. Five participants with missing data for covariates were excluded from this analysis (n = 3055)
